CN104399044A - Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation - Google Patents

Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation Download PDF

Info

Publication number
CN104399044A
CN104399044A CN201410727857.3A CN201410727857A CN104399044A CN 104399044 A CN104399044 A CN 104399044A CN 201410727857 A CN201410727857 A CN 201410727857A CN 104399044 A CN104399044 A CN 104399044A
Authority
CN
China
Prior art keywords
parts
radix
veterinary medicine
arthritis
chinese veterinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410727857.3A
Other languages
Chinese (zh)
Inventor
史亚林
李亚娥
刘伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Houyi Pharmaceutical Co Ltd
Original Assignee
Zhengzhou Houyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Houyi Pharmaceutical Co Ltd filed Critical Zhengzhou Houyi Pharmaceutical Co Ltd
Priority to CN201410727857.3A priority Critical patent/CN104399044A/en
Publication of CN104399044A publication Critical patent/CN104399044A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/27Asclepiadaceae (Milkweed family), e.g. hoya
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285Aucklandia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/37Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/66Papaveraceae (Poppy family), e.g. bloodroot
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation. The Chinese veterinary medicine consists of the following crude drugs in parts by weight: 10-20 parts of salvia miltiorrhiza, 8-12 parts of radix aucklandiae, 8-12 parts of corydalis yanhusuo, 8-15 parts of red ginseng, 5-25 parts of large-headed atractylodes, 8-25 parts of tripterygium glycosides, 5-15 parts of ephedra, 10-15 parts of sodium sulfate, 10-20 parts of cynanchum paniculatum, 8-15 parts of licorice root, 10-20 parts of pseudo-ginseng and 5-20 parts of dried ginger. Compared with the prior art, the traditional Chinese veterinary medicine disclosed by the invention has the characteristics of careful selection for the medicinal material, high selectivity, treatment of the symptoms and the causes, high convenience for taking, higher response, easily-accessible raw material and good prospect; the traditional Chinese veterinary medicine has the functions of reinforcing qi and blood, decreasing swelling to relieve pain and removing stasis to dredge stagnancy; after the diseases are cured, the relapse is avoided; the traditional Chinese veterinary medicine can be internally taken by adopting decocted traditional Chinese or can be prepared into pills, capsules and the like and is short in relative treatment course and good in curative effect; the crude drugs are common and easily obtained; the Chinese veterinary medicine is easily prepared and is suitable for batch production. The Chinese veterinary medicine also has the characteristics of short treatment course, good curative effect, high cure rate, greater marker potential and good development and application prospect.

Description

The herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny
Technical field
The invention belongs to herbal medicine technical field, be specifically related to the herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny.
Background technology
Clinical common arthritis mainly comprises following several: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gouty arthritis, traumatic arthritis, hyperosteogeny etc.Arthritis general reference occurs in the inflammatory diseases of human synovial and surrounding tissue thereof, and along with the change of life style and natural environment, the scorching phenomenon of joint of animal becomes more and more serious.Clinical manifestation be joint red, swollen, hot, bitterly, functional disorder and joint deformity, severe patient causes joint disabled, affects orthobiosis.At present, the method for the treatment of of arthritis is more, and as " a surname's numbness soup ", " Radix Angelicae Sinensis picks up pain soup " etc., though they have certain curative effect to arthritis, now all Chinese medicine preparation still exist curative effect to rebound slowly, easily, be difficult to the deficiencies such as radical cure, still unsatisfactory.
At present, the Western medicine for the treatment of of arthritis is divided into a line, two wires and three line three classes by people.Except this three classes Western medicine, the Chinese medicine in addition for the treatment of rheumatoid arthritis.
(1) first-line drug, i.e. NSAID (non-steroidal anti-inflammatory drug).First-line drug has good easing pain and diminishing inflammation effect, and the symptoms such as arthroncus, pain, stiff, dysfunction can be made to alleviate rapidly.The first-line drug that treatment rheumatoid arthritis is commonly used comprises: salicylic acid, as aspirin, sodium salicylate etc.; Acetic acid class (i.e. indoles), as indometacin, Sulindac etc.; Phenoxy propionic acid, as ibuprofen (ibuprofen is the slow releasing capsule of ibuprofen), naproxen etc.; Fenamic acids, as flufenamic acid, Diclofenac (its product has Dai Fen, Ying Taiqing, diclofenac) etc.; Former times health class, as piroxicam, meloxicam (trade name mobic) etc.; Pyrazolone, as protected Qin Song, Qiang Bao Qin Song etc.; Former times dry goods, as celecoxib (trade name celecoxib), rofecoxib (trade name ten thousand promise) etc.; Other classes, as nimesulide, nabumetone etc.
(2) Second line Drug onset is slow, the course for the treatment of is long, therefore also referred to as chronic drug.Second line Drug is more trending towards effecting a permanent cure to using of rheumatoid arthritis.This kind of drug main will comprise: the immunosuppressant such as methotrexate, cyclophosphamide, azathioprine, ciclosporin, leflunomide (trade name Ai Ruohua), and sulfasalazine, golden preparation (as Ruide), Beracilline, antimalarial drug etc.
(3) three line medicines, i.e. steroidal anti-inflammatory medicine, be otherwise known as hormone drug.Such medicine has significant curative effect rapidly to the fever of patient with rheumatoid arthritis, arthralgia and swelling.But when using amcinonide, must send for a doctor strictly to grasp dosage and the course for the treatment of, otherwise larger side effect can be produced, lose more than gain.Three conventional line medicines comprise: prednisone, meticortelone, dexamethasone, bent peace Susong, Diprospan etc.
(4) Chinese medicine.Chinese medicine can removing cold and wind damp and hot evil, unclog and readjust meridians joint, reach symptom management, shorten the object of the course of disease, relief of symptoms.
Summary of the invention
The technical problem to be solved in the present invention is current, first-line drug instant effect in the Western medicine for the treatment of joint of animal inflammation, but easily recur, Second line Drug onset is slow, the course for the treatment of is long, three line medicines easily produce toxic and side effects, for solving the problem, the invention provides the herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny.
The object of the invention is to realize in the following manner:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10-20 part, Radix Aucklandiae 8-12 part, Rhizoma Corydalis 8-12 part, Radix Ginseng Rubra 8-15 part, Rhizoma Atractylodis Macrocephalae 5-25 part, Radix Tripterygii Wilfordii 8-25 part, Herba Ephedrae 5-15 part, Natrii Sulfas 10-15 part, Radix Cynanchi Paniculati 10-20 part, Radix Glycyrrhizae 8-15 part, Radix Notoginseng 10-20 part, Rhizoma Zingiberis 5-20 part.
Be made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 15 parts, the Radix Aucklandiae 10 parts, Rhizoma Corydalis 10 parts, Radix Ginseng Rubra 12 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Tripterygii Wilfordii 10 parts, 10 parts, Herba Ephedrae, 10 parts, Natrii Sulfas, Radix Cynanchi Paniculati 15 parts, 12 parts, Radix Glycyrrhizae, Radix Notoginseng 15 parts, Rhizoma Zingiberis 10 parts.
Medicine of the present invention usually adopts and is fried into Chinese medicine decoction and takes orally, and the conventional method of Chinese medicine preparation also can be adopted to be prepared into multiple conventional oral preparations.Such as by above-mentioned formula material medicine pulverize mix homogeneously, pill, capsule or soft extract can be made.The present invention is with Radix Salviae Miltiorrhizae, the Radix Aucklandiae, Rhizoma Corydalis, Radix Tripterygii Wilfordii, Herba Ephedrae, Natrii Sulfas for monarch drug, and Radix Notoginseng, Radix Cynanchi Paniculati, Radix Glycyrrhizae are ministerial drug, and Rhizoma Zingiberis is adjuvant drug, and Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, for making medicine, have the effect of dispelling cold by warming the meridian, promoting blood circulation and stopping pain.
Radix Ginseng Rubra is selected to be because Radix Ginseng Rubra is sweet, warm in side of the present invention.There is strongly invigorating primordial QI, nourishing qi to stop, effect that multiple arteries and veins takes off admittedly; The bitter sweet temperature of the Rhizoma Atractylodis Macrocephalae, invigorating the spleen and benefiting QI, dampness diuretic.The pharmacodynamic feature of this two tastes medicine is mainly rich in nutrition, strengthening the tendons and bones, nourishing the liver and kidney, the effect consolidated.
In order to reach effective treatment, treating both the principal and secondary aspects of a disease, this invention medicine also uses the Radix Aucklandiae, Rhizoma Corydalis, Radix Tripterygii Wilfordii, Herba Ephedrae, Natrii Sulfas combination.A few taste medicine focuses on dredge the meridian passage, dispelling cold and removing dampness, eliminate stagnation and dissolve phlegm, reducing swelling and alleviating pain above, and excretion pyretic toxicity, unimpeded blood reaches effect of reducing swelling and alleviating pain.
In order to obtain optimum curative effect, medicine of the present invention also adds Radix Cynanchi Paniculati, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae, Radix Notoginseng and Rhizoma Zingiberis combination on the basis of said medicine.Because Radix Cynanchi Paniculati is warm in nature, there is the effect of removing dampness of dispeling the wind; Radix Glycyrrhizae is sweet flat, the effect of relieving spasm to stop pain; Radix Salviae Miltiorrhizae bitter in the mouth, cold nature; GUIXIN, Liver Channel.Promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, clear away heart-fire relieving restlessness, nourishing blood to tranquillize the mind; Radix Notoginseng is warm in nature, acrid in the mouth, has scattered silt hemostasis, effect of subduing swelling and relieving pain; Rhizoma Zingiberis acrid in the mouth, hot in nature.Return spleen, stomach, the heart, lung meridian, warming spleen and stomach for dispelling cold, recuperating depleted YANG is promoted blood circulation, dampness expectorant, warming the lung to resolve fluid-retention.Above five medicines focus on mediation, alleviate and cushion toxicity and untoward reaction, are aided with effect of Jiedu Yiqi simultaneously.
Above-mentioned 12 taste medicines combine by medicine of the present invention, particularly combine with above-mentioned weight proportion, can reducing swelling and alleviating pain, unimpeded blood, and blood stasis dispelling leads to stagnant, recover effect of function of joint, and the curative effect for the treatment of rheumatoid arthritis is best.The present invention suits the remedy to the case, specificity is strong, treating both the principal and secondary aspects of a disease, evident in efficacy to rheumatoid arthritis, recovers function of joint fast, and once healing, is difficult to recurrence.
The present invention is the herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny, compared with prior art, has following characteristics: one is that medical material is selected, and specificity is strong, treating both the principal and secondary aspects of a disease.This invention adopts rich in nutrition, reducing swelling and alleviating pain, logical stagnant by silt, and once healing, is difficult to recurrence.Two is taking conveniences, quick result.This medicine can adopt fried oral medicinal herb, also can be made into pill, capsule etc., relative short treating period, good effect.Three is that raw material is easily got, promise well.These crude drug are common easily to be got, and easily, suitable batch is produced in preparation.Short treating period of the present invention, good effect, cure rate is high, and market potential is large, and development prospect is good.
Detailed description of the invention
Embodiment 1:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10-20 part, Radix Aucklandiae 8-12 part, Rhizoma Corydalis 8-12 part, Radix Ginseng Rubra 8-15 part, Rhizoma Atractylodis Macrocephalae 5-25 part, Radix Tripterygii Wilfordii 8-25 part, Herba Ephedrae 5-15 part, Natrii Sulfas 10-15 part, Radix Cynanchi Paniculati 10-20 part, Radix Glycyrrhizae 8-15 part, Radix Notoginseng 10-20 part, Rhizoma Zingiberis 5-20 part.
Embodiment 2:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10g, Radix Aucklandiae 8g, Rhizoma Corydalis 8g, Radix Ginseng Rubra 8g, Rhizoma Atractylodis Macrocephalae 5g, Radix Tripterygii Wilfordii 8g, Herba Ephedrae 5g, Natrii Sulfas 10g, Radix Cynanchi Paniculati 10g, Radix Glycyrrhizae 8g, Radix Notoginseng 10g, Rhizoma Zingiberis 5g.
Embodiment 3:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 12g, Radix Aucklandiae 9g, Rhizoma Corydalis 9g, Radix Ginseng Rubra 9g, Rhizoma Atractylodis Macrocephalae 8g, Radix Tripterygii Wilfordii 12g, Herba Ephedrae 7g, Natrii Sulfas 11g, Radix Cynanchi Paniculati 12g, Radix Glycyrrhizae 9g, Radix Notoginseng 12g, Rhizoma Zingiberis 9g.
Embodiment 4:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 14g, Radix Aucklandiae 10g, Rhizoma Corydalis 10g, Radix Ginseng Rubra 10g, Rhizoma Atractylodis Macrocephalae 12g, Radix Tripterygii Wilfordii 16g, Herba Ephedrae 9g, Natrii Sulfas 12g, Radix Cynanchi Paniculati 14g, Radix Glycyrrhizae 10g, Radix Notoginseng 14g, Rhizoma Zingiberis 12g.
Embodiment 5:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 16g, Radix Aucklandiae 10.5g, Rhizoma Corydalis 10.5g, Radix Ginseng Rubra 12g, Rhizoma Atractylodis Macrocephalae 16g, Radix Tripterygii Wilfordii 20g, Herba Ephedrae 11g, Natrii Sulfas 13g, Radix Cynanchi Paniculati 16g, Radix Glycyrrhizae 12g, Radix Notoginseng 16g, Rhizoma Zingiberis 15g.
Embodiment 6:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 18g, Radix Aucklandiae 11g, Rhizoma Corydalis 11g, Radix Ginseng Rubra 14g, Rhizoma Atractylodis Macrocephalae 20g, Radix Tripterygii Wilfordii 22g, Herba Ephedrae 13g, Natrii Sulfas 14g, Radix Cynanchi Paniculati 18g, Radix Glycyrrhizae 14g, Radix Notoginseng 18g, Rhizoma Zingiberis 17g.
Embodiment 7:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 20g, Radix Aucklandiae 12g, Rhizoma Corydalis 12g, Radix Ginseng Rubra 15g, Rhizoma Atractylodis Macrocephalae 25g, Radix Tripterygii Wilfordii 25g, Herba Ephedrae 15g, Natrii Sulfas 15g, Radix Cynanchi Paniculati 20g, Radix Glycyrrhizae 15g, Radix Notoginseng 20g, Rhizoma Zingiberis 20g.
Embodiment 8:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 15g, Radix Aucklandiae 10g, Rhizoma Corydalis 10g, Radix Ginseng Rubra 12g, Rhizoma Atractylodis Macrocephalae 20g, Radix Tripterygii Wilfordii 10g, Herba Ephedrae 10g, Natrii Sulfas 10g, Radix Cynanchi Paniculati 15g, Radix Glycyrrhizae 12g, Radix Notoginseng 15g, Rhizoma Zingiberis 10g.
Clinical experimental study
1. basic condition
2009 to 2013, Canis familiaris L. Canis familiaris L. 160 example of diagnosis and treatment arthritis, rheumatoid arthritis and hyperosteogeny.Wherein Labrador Retriever 65 example, Sa Moye 55 example, golden hair 40 example; Age 0-1 year 43 example, 1-3 year 54 example, 3-6 year 63 example.Early stage 50 examples in patient with rheumatoid arthritis, mid-term 67 is routine, and late period 43 is routine.
2. diagnostic criteria
To patient with rheumatoid arthritis by medical science by stages universal standard diagnostic classification be in early days, mid-term, late period.
Early stage: most affected joints is to swelling and ache and limitation of activity; But x-ray only shows soft tissue swelling and osteoporosis.
Mid-term: part affected joints functional activity is obviously limited; X-ray film display joint space narrows and bone corrosion in various degree.
Late period: various deformity appears in most affected joints, and fiber is tetanic, movable difficulty, X-ray film display joint heavy damage, dislocation or fusion.
3. Therapeutic Method
The fried Chinese medicine decoction of the prescription provided by embodiment 8 is taken orally.Every day 1 pair, decoct twice, the morning and evening take orally, 30 days courses for the treatment of, treat most elder and take continuously five months 150 days, be i.e. 5 courses for the treatment of.
4. criterion of therapeutical effect
Effective: after treatment, affected joints swells and ache and is clearly better or disappears, function of joint is improved or is recovered normal, and can maintain more than 3 months after drug withdrawal.
Take a turn for the better: after treatment, affected joints pain or swell and ache take a favorable turn.
Invalid: more than treatment 1-3 the course for the treatment of (30 days per courses for the treatment of), affected joints swells and ache without taking a turn for the better.
5. therapeutic outcome
Therapeutic outcome is in table 1 and table 2.
Table 1 Rheumatoid Arthritis after treatment is observed
Table 2 is observed Rheumatoid Arthritis through treating five months
Rheumatoid arthritis classification In early days Mid-term Late period
Case before treatment 50 67 43
Case after treatment 0 2 4
Total effective rate 100% 97% 91%
Show from table 1 observation of curative effect result, 5 months are being treated to the dog class suffering from rheumatoid arthritis, observe 5 middle of the month, by Drug therapy rheumatoid arthritis 160 example of the present invention, effective 143 examples of result, obvious effective rate 90%, take a turn for the better 13 examples, and improvement rate is 8%, invalid 4 examples, inefficiency is 2%, and total effective rate reaches 98%.
Show from table 2 observation of curative effect result, medicine of the present invention is to the rheumatoid arthritis dog class 160 example treatment observation of curative effect of 5 months, result is to rheumatoid arthritis early stage patient total effective rate 100%, and mid-term, patient's total effective rate was 97%, and patients with terminal total effective rate is 91%.
On the whole, the present invention has prepared the medicine that a kind of Chinese medicine is used for the treatment of arthritis, rheumatoid arthritis and hyperosteogeny, short treating period of the present invention, good effect, and cure rate is high, and market potential is large, and development prospect is good.
Above-described is only the preferred embodiment of the present invention, it should be pointed out that for a person skilled in the art, and not departing under general idea prerequisite of the present invention, can also make some changes and improvements, these also should be considered as protection scope of the present invention.

Claims (2)

1. a herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is characterized in that: be made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10-20 part, Radix Aucklandiae 8-12 part, Rhizoma Corydalis 8-12 part, Radix Ginseng Rubra 8-15 part, Rhizoma Atractylodis Macrocephalae 5-25 part, Radix Tripterygii Wilfordii 8-25 part, Herba Ephedrae 5-15 part, Natrii Sulfas 10-15 part, Radix Cynanchi Paniculati 10-20 part, Radix Glycyrrhizae 8-15 part, Radix Notoginseng 10-20 part, Rhizoma Zingiberis 5-20 part.
2. the herbal medicine of a kind for the treatment of of arthritis according to claim 1, rheumatoid arthritis and hyperosteogeny, is characterized in that: be made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 15 parts, the Radix Aucklandiae 10 parts, Rhizoma Corydalis 10 parts, Radix Ginseng Rubra 12 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Tripterygii Wilfordii 10 parts, 10 parts, Herba Ephedrae, 10 parts, Natrii Sulfas, Radix Cynanchi Paniculati 15 parts, 12 parts, Radix Glycyrrhizae, Radix Notoginseng 15 parts, Rhizoma Zingiberis 10 parts.
CN201410727857.3A 2014-12-01 2014-12-01 Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation Pending CN104399044A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410727857.3A CN104399044A (en) 2014-12-01 2014-12-01 Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410727857.3A CN104399044A (en) 2014-12-01 2014-12-01 Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation

Publications (1)

Publication Number Publication Date
CN104399044A true CN104399044A (en) 2015-03-11

Family

ID=52636753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410727857.3A Pending CN104399044A (en) 2014-12-01 2014-12-01 Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation

Country Status (1)

Country Link
CN (1) CN104399044A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1977899A (en) * 2005-12-03 2007-06-13 颜正东 Medicine for treating rheumatoid arthritis
WO2007149504A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1977899A (en) * 2005-12-03 2007-06-13 颜正东 Medicine for treating rheumatoid arthritis
WO2007149504A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
苏广容等: "理中汤加味治疗类风湿的体会", 《实用中医内科杂志》 *

Similar Documents

Publication Publication Date Title
CN103860699A (en) Pharmaceutical composition for radically treating hypertension, hyperlipidemia and hyperglycemia
CN103182019B (en) Traditional Chinese medicine composition for treating ROU (recurrent oral ulcer)
CN101569739A (en) Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof
CN105535577A (en) Medicament to reduce the side effects of chemotherapy for tumor patient
CN101658657B (en) Drug for treating chronic cholecystitis
CN104337989A (en) Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout
CN115282229A (en) Traditional Chinese medicine composition for treating coronary heart disease with syndrome of qi deficiency and blood stasis and preparation method thereof
CN104306847A (en) Six-ingredient qi-tonifying capsule and preparation process thereof
CN104740405B (en) A kind of Chinese medicine preparation and preparation method for treating anaphylactoid purpura renal damage
CN104399044A (en) Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation
CN103585471B (en) Traditional Chinese medicine composition for treating thrombocytopenia
CN110841007B (en) Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof
CN105287798A (en) Lipid-lowering and slimming recovery pill
CN104096202A (en) Medicine for treating autumn diarrhea and preparation method of medicine
CN104606427A (en) Schefflera arboricola-contained traditional Chinese medicinal composition
CN105327024A (en) Traditional Chinese medicine preparation for treating rheumatoid arthritis
CN104606377A (en) Traditional Chinese medicinal composition for treating gastritis
CN104826068A (en) Medicine for expelling wind and eliminating dampness and preparation method of medicine
CN104587122A (en) Traditional Chinese medicine composition for treating chronic gastritis
CN104524540A (en) Traditional Chinese medicine composition for treating gallbladder polyps
CN104606426A (en) Traditional Chinese medicinal composition preparation for treating chronic gastritis and preparation method thereof
CN104173952A (en) Traditional Chinese medicine composition for treating benign ovarian tumor
CN103301309A (en) Traditional Chinese herbal medicine for treating laryngocarcinoma and esophagus cancer
CN102028810A (en) Traditional Chinese medicine for treating lumbar intervertebral disc protrusion
CN105126039A (en) Chinese herb preparation for treating caecum granuloma and preparing method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150311

RJ01 Rejection of invention patent application after publication